UNSPSC 51385103: Amixetrine hydrochloride

This classification denotes a nonsteroidal antiinflammatory drug C17H27NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VJB5017RC5, chemically known as pyrrolidine, 1-(2-(3-methylbutoxy)-2-phenylethyl)-, hydrochloride (1:1), but more generally known as amixetrine hydrochloride, which bears US NIH Compound Identifier 170333. Most nations, for tariff and trade purposes, schedule amixetrine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, AMIXETRINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

SMILES: CC(C)CCOC(CN1CCCC1)C2CCCCC2.CL.

UNSPSC 51385103 Amixetrine hydrochloride is a Commodity code that nominally names a specific pharmaceutical ingredient, but recent state and local solicitations tagged under it actually procure a far broader array of medications and health-system supplies — including naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. The mismatch between the code's specific name and the actual scope of purchases suggests that state and local procurement offices are using this code as a catch-all for pharmaceutical procurement when more granular codes are unavailable or impractical. Issuing bodies span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance with participating states including Oregon). The work involves supply of finished pharmaceutical products and medical consumables, with vendor responsibilities typically including compliance with FDA manufacturing standards, Drug Supply Chain Security Act requirements, insurance coverage, and E-Verify employment verification.

Recent activity concentrates in Florida, Texas, and Minnesota, with the Minnesota cooperative representing a multistate footprint. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the county health building, fixed-fee pricing, and a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission issued an RFI (HHS0017013, response deadline April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription fulfillment programs before issuing a formal RFP. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products across state and local government facilities, with awards effective July 1, 2026, requiring vendor compliance with cGMP and DSCSA standards, maintenance of relationships with specified wholesalers, and submission of pricing in multiple formats (flat price, net price, or WAC-minus structures).